Human immunodeficiency virus type-1 (HIV-1), the causative agent of acquired immune deficiency syndrome (AIDS), has infected ~60 million people worldwide and caused over 25 million deaths. Sexual transmission is the major route of HIV-1 infection and factors that promote this infectious route have recently been identified in semen. Fragments of prostatic acid phosphatase are a major component of semen and form amyloid fibrils that bind HIV virions and can promote infection by several orders of magnitude up to 105-fold. Therefore, a potential preventative strategy is to deploy agents that eliminate these amyloid forms, which are termed Semen-derived Enhancer of Virus Infection (SEVI) fibrils. Unfortunately, amyloid fibrils are notoriously stable and difficult to eradicate. In other settings, they are connected with various fatal neurodegenerative disorders. However, various microbes have harnessed the amyloid form for beneficial purposes, and systems have evolved that can rapidly reverse amyloid formation. One natural protein has emerged that resolves amyloid fibrils with unprecedented alacrity: the protein disaggregase, Hsp104. Hsp104 rapidly solubilizes amyloid forms of several proteins, including yeast prion proteins Sup35 and Ure2, as well as ?-synuclein, which forms amyloid fibrils in Parkinson's disease. We hypothesize that Hsp104 or SEVI-optimized variants can be generated to rapidly dissolve or remodel SEVI fibrils and thereby diminish SEVI-enhanced HIV infection. Thus, we aim to: (1) Develop Hsp104 variants that rapidly disassemble SEVI fibrils~ and (2) Determine whether disassembled products have diminished ability to promote HIV infection. These studies will provide the foundations for developing SEVI disaggregases as preventative agents with the ultimate goal of incorporating them into a gel or solution that dissolves SEVI fibrils in semen and reduces sexual transmission of HIV. The ability to reverse fibril formation (rather than simply inhibit it) and blck sexual transmission of HIV will provide a powerful and much needed weapon against the global HIV/AIDS pandemic. Our approach of targeting a host protein conformer (SEVI fibrils) is fundamentally different from traditional microbicidal approaches that target the virus, and this strategy is anticipated to synergize with direct antiviral strategies.

Public Health Relevance

Human immunodeficiency virus type-1 (HIV-1), the virus that causes acquired immune deficiency syndrome (AIDS), is transmitted sexually and HIV-1 infection is enhanced approximately 100,000-fold by fibers formed by host proteins in human semen. Here, we plan to engineer specific enzymes that target and eliminate these host protein fibers and thereby block HIV-1 infection. Realization of our objectives will empower urgently needed new strategies to prevent HIV-1 infection and combat the global HIV/AIDS pandemic.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HD074510-02
Application #
8501616
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Russo, Denise
Project Start
2012-07-01
Project End
2014-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$189,800
Indirect Cost
$71,175
Name
University of Pennsylvania
Department
Biochemistry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Seither, Katelyn M; McMahon, Heather A; Singh, Nikita et al. (2014) Specific aromatic foldamers potently inhibit spontaneous and seeded A?42 and A?43 fibril assembly. Biochem J 464:85-98
Jackrel, Meredith E; Tariq, Amber; Yee, Keolamau et al. (2014) Isolating potentiated Hsp104 variants using yeast proteinopathy models. J Vis Exp :e52089
Jackrel, Meredith E; Shorter, James (2014) Reversing deleterious protein aggregation with re-engineered protein disaggregases. Cell Cycle 13:1379-83
Jackrel, Meredith E; DeSantis, Morgan E; Martinez, Bryan A et al. (2014) Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156:170-82
Jackrel, Meredith E; Shorter, James (2014) Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Dis Model Mech 7:1175-84
Li, Yun R; King, Oliver D; Shorter, James et al. (2013) Stress granules as crucibles of ALS pathogenesis. J Cell Biol 201:361-72
Torrente, Mariana P; Shorter, James (2013) The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins. Prion 7:457-63